• 1.

    Hoppe B. An update on primary hyperoxaluria. Nat Rev Nephrol 2010; 8:467475. doi: 10.1038/nrneph.2012.113

  • 2.

    Cochat P, Rumsby G. Primary hyperoxaluria. N Engl J Med 2013; 369:649658. doi: 10.1056/NEJMra1301564

  • 3.

    US National Library of Medicine. OXLUMO - lumasiran injection, solution. DailyMed (Alnylam Pharmaceuticals, Inc.). https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=16985a31-f5e4-4557-9266-fc78d4bc5055#section-8.1

    • Search Google Scholar
    • Export Citation
  • 4.

    Alnylam Pharmaceuticals. A Study to Evaluate Lumasiran in Children and Adults with Primary Hyperoxaluria Type 1 (ILLUMINATE-A). ClinicalTrials.gov: NCT03681184. https://clinicaltrials.gov/ct2/show/results/NCT03681184?view=results

    • Search Google Scholar
    • Export Citation
  • 5.

    US Food and Drug Administration. FDA Approves First Drug to Treat Rare Metabolic Disorder. November 23, 2020. https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-treat-rare-metabolic-disorder

    • Search Google Scholar
    • Export Citation

First of Its Kind Treatment for Primary Hyperoxaluria Wins Approval, Holds Promise

  • 1 Ray Bignall II, MD, is Director, Kidney Health Advocacy and Community Engagement, Division of Nephrology and Hypertension, Nationwide Children's Hospital, and Clinical Assistant Professor of Pediatrics, The Ohio State University College of Medicine, Columbus, OH.
Restricted access
Save